[
  {
    "ts": null,
    "headline": "Down 50%, Should You Buy the Dip on Pfizer?",
    "summary": "Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.",
    "url": "https://finnhub.io/api/news?id=7e4baf3fb275c621d97cfcd13a518d938f5d3ecd28211ba7ccccf0114f888a08",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765316100,
      "headline": "Down 50%, Should You Buy the Dip on Pfizer?",
      "id": 137750326,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer's stock has fallen by more than 50% from its 2021 highs and faces some headwinds, but remains worth a deep dive for long-term investors.",
      "url": "https://finnhub.io/api/news?id=7e4baf3fb275c621d97cfcd13a518d938f5d3ecd28211ba7ccccf0114f888a08"
    }
  },
  {
    "ts": null,
    "headline": "What Pfizer (PFE)'s GLP-1 Obesity Deal and Hemophilia Data Mean For Shareholders",
    "summary": "Recently, Pfizer Inc. announced an exclusive global collaboration and license agreement with YaoPharma to develop, manufacture and commercialize YP05002, an oral small-molecule GLP-1 receptor agonist currently in Phase 1 for chronic weight management, alongside new Phase 3 data showing HYMPAVZI improved bleeding outcomes for people with hemophilia A or B with inhibitors. The YaoPharma deal, which includes a US$150 million upfront payment and potential milestones of up to US$1.94 billion plus...",
    "url": "https://finnhub.io/api/news?id=19721642e74a961eb2f20cfa3238327bf7ea225b8dcdc07d109379e3fc99b51d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765314766,
      "headline": "What Pfizer (PFE)'s GLP-1 Obesity Deal and Hemophilia Data Mean For Shareholders",
      "id": 137750327,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Recently, Pfizer Inc. announced an exclusive global collaboration and license agreement with YaoPharma to develop, manufacture and commercialize YP05002, an oral small-molecule GLP-1 receptor agonist currently in Phase 1 for chronic weight management, alongside new Phase 3 data showing HYMPAVZI improved bleeding outcomes for people with hemophilia A or B with inhibitors. The YaoPharma deal, which includes a US$150 million upfront payment and potential milestones of up to US$1.94 billion plus...",
      "url": "https://finnhub.io/api/news?id=19721642e74a961eb2f20cfa3238327bf7ea225b8dcdc07d109379e3fc99b51d"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
    "summary": "Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.6% and th",
    "url": "https://finnhub.io/api/news?id=ae30ad34c1784e8556bc034f0b86488c910067c39f9519c671d365f6535af064",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765313988,
      "headline": "Sector Update: Health Care Stocks Softer Late Afternoon",
      "id": 137750328,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 0.6% and th",
      "url": "https://finnhub.io/api/news?id=ae30ad34c1784e8556bc034f0b86488c910067c39f9519c671d365f6535af064"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Strikes Licensing Deal For Chinese Company's Obesity Drug Candidate",
    "summary": "Pfizer (PFE) said Tuesday that it will develop Chinese drug manufacturer YaoPharma's weight loss the",
    "url": "https://finnhub.io/api/news?id=49d90cf14576aa4ac1b6feadeb049c515db330837f7371ccdf2f7ca20fdf3653",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765313732,
      "headline": "Pfizer Strikes Licensing Deal For Chinese Company's Obesity Drug Candidate",
      "id": 137750329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) said Tuesday that it will develop Chinese drug manufacturer YaoPharma's weight loss the",
      "url": "https://finnhub.io/api/news?id=49d90cf14576aa4ac1b6feadeb049c515db330837f7371ccdf2f7ca20fdf3653"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
    "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
    "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765305600,
      "headline": "Pharma ETFs to Gain From Landmark UK-US Zero-Tariff Deal",
      "id": 137749832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE are poised to surge as the UK-US zero-tariff deal raises UK drug prices and strengthens major U.S. players' outlook.",
      "url": "https://finnhub.io/api/news?id=18c6c518fd9ae16d7e56818f8e62791ae026a9ff69d57b0ee4933283232cc6a8"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill",
    "summary": "Agreement deepens company's push into fast-growing weight-loss market",
    "url": "https://finnhub.io/api/news?id=3744d48e378f60ff86de073952ace1f6ad4ba70ce9260040b2d3200590c4d7f8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765301402,
      "headline": "Pfizer Expands Obesity Pipeline With Up to $2.1 Billion Deal for YaoPharma Pill",
      "id": 137742557,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Agreement deepens company's push into fast-growing weight-loss market",
      "url": "https://finnhub.io/api/news?id=3744d48e378f60ff86de073952ace1f6ad4ba70ce9260040b2d3200590c4d7f8"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Nvidia H200 AI Chips' China Access; Google's EU Antitrust Probe; Amazon New York Drivers Join Teamsters Union",
    "summary": "All three major US stock indexes were edging higher in late-morning trading on Tuesday after the Fed",
    "url": "https://finnhub.io/api/news?id=a3e7f50ebd9055239ec39df11c2e658f8ae2c9b9850952612c42b475ae7877b3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765299997,
      "headline": "Top Midday Stories: Nvidia H200 AI Chips' China Access; Google's EU Antitrust Probe; Amazon New York Drivers Join Teamsters Union",
      "id": 137742410,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "All three major US stock indexes were edging higher in late-morning trading on Tuesday after the Fed",
      "url": "https://finnhub.io/api/news?id=a3e7f50ebd9055239ec39df11c2e658f8ae2c9b9850952612c42b475ae7877b3"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.",
    "summary": "Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.",
    "url": "https://finnhub.io/api/news?id=78c46051a4119b40bfcaee2524a60fec30a54ecbb5097ba53ab055009cf40c50",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765299000,
      "headline": "Pfizer Turns to China for Trial Weight Loss Drug. Congress Is Worried About Chinese Biotechs.",
      "id": 137742558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Big American drugmakers are hunting for novel weight loss drugs in the labs of China’s biotech industry, while U.S. authorities try to undercut the growing Chinese biotech sector.",
      "url": "https://finnhub.io/api/news?id=78c46051a4119b40bfcaee2524a60fec30a54ecbb5097ba53ab055009cf40c50"
    }
  },
  {
    "ts": null,
    "headline": "In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?",
    "summary": "In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.",
    "url": "https://finnhub.io/api/news?id=8d87d77ff69a12b94520f460402b6929bfba63b3e41db2aaf5b1aa17e8ec0381",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765296676,
      "headline": "In The 'Uber Bull' Biotech Market, Is Structure The Next Metsera?",
      "id": 137742561,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "In a post-Metsera world, Structure Therapeutics could be the next big takeover candidate, analysts said Tuesday.",
      "url": "https://finnhub.io/api/news?id=8d87d77ff69a12b94520f460402b6929bfba63b3e41db2aaf5b1aa17e8ec0381"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA",
    "summary": "This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.",
    "url": "https://finnhub.io/api/news?id=8c8c3814b8df709af87692fefc473cf545cdab496aeffeb9ad8de5c84029cd25",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765290373,
      "headline": "Pfizer gains another obesity asset with $2bn deal for YaoPharma’s GLP-1RA",
      "id": 137740279,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "This comes just under a month after Pfizer finalised a deal to acquire Metsera following a bidding war with Novo Nordisk.",
      "url": "https://finnhub.io/api/news?id=8c8c3814b8df709af87692fefc473cf545cdab496aeffeb9ad8de5c84029cd25"
    }
  },
  {
    "ts": null,
    "headline": "Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement",
    "summary": "Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. (\"Yao Pharma\"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece",
    "url": "https://finnhub.io/api/news?id=cb7414e024af2b03d402ba4af7fc496d00a2f21a2b14affe0e1969df2fb7861f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765281300,
      "headline": "Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement",
      "id": 137740280,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. (\"Yao Pharma\"), Shanghai Fosun Pharmaceutical Industrial Development Company Limited, and Pfizer Inc. (NYSE: PFE) have entered into an exclusive collaboration and license agreement. Under this agreement, Yao Pharma grants Pfizer an exclusive worldwide license for the development, use, manufacturing, and commercialization of oral small-molecule glucagon-like peptide-1 rece",
      "url": "https://finnhub.io/api/news?id=cb7414e024af2b03d402ba4af7fc496d00a2f21a2b14affe0e1969df2fb7861f"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma",
    "summary": "NEW YORK, December 09, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight mana",
    "url": "https://finnhub.io/api/news?id=520759a51c97be99f26243ef0855d9703d7e715525539b41b9dccab7f6e36cd1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765279800,
      "headline": "Pfizer Enters into Exclusive Collaboration and License Agreement with YaoPharma",
      "id": 137740281,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, December 09, 2025--Pfizer Inc. (NYSE: PFE) today announced it has entered into an exclusive global collaboration and license agreement with YaoPharma, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Limited (02196.HK and 600106.SH), a leading innovation-driven global healthcare company, for the development, manufacturing and commercialization of YP05002, a small molecule glucagon-like peptide 1 (GLP-1) receptor agonist currently in Phase 1 development for chronic weight mana",
      "url": "https://finnhub.io/api/news?id=520759a51c97be99f26243ef0855d9703d7e715525539b41b9dccab7f6e36cd1"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill",
    "summary": "The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month.",
    "url": "https://finnhub.io/api/news?id=b77a324d46c03ec78cb392b377522475833bfdb93c7ce79c18ba6373e432f43a",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765278872,
      "headline": "Pfizer adds to obesity bet with up to $2.1 billion deal to develop Chinese company's pill ",
      "id": 137741745,
      "image": "https://image.cnbcfm.com/api/v1/image/107364661-17062120762021-04-23t143705z_84240954_rc2q1n97o4om_rtrmadp_0_health-coronavirus-eu-pfizer.jpeg?v=1706212117&w=1920&h=1080",
      "related": "PFE",
      "source": "CNBC",
      "summary": "The deal will help Pfizer beef up and diversify its obesity drug pipeline following its $10 billion acquisition of obesity biotech Metsera last month. ",
      "url": "https://finnhub.io/api/news?id=b77a324d46c03ec78cb392b377522475833bfdb93c7ce79c18ba6373e432f43a"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer dips into China for another try at an obesity pill",
    "summary": "A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.",
    "url": "https://finnhub.io/api/news?id=8947d730aae5319765ae08e2828573983b01007bcf5b7e7e690eb635d706980e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765277940,
      "headline": "Pfizer dips into China for another try at an obesity pill",
      "id": 137742564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight loss medication, an area where its internal research has struggled.",
      "url": "https://finnhub.io/api/news?id=8947d730aae5319765ae08e2828573983b01007bcf5b7e7e690eb635d706980e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains",
    "summary": "Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds.",
    "url": "https://finnhub.io/api/news?id=50a8085ce11f95d1bb6dc7007d3590bbd4a61b3fe225d7f33fd4c0332781e962",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765277108,
      "headline": "Pfizer: The Most Powerful Drug Pipeline In Pharma Could Deliver Major Long-Term Gains",
      "id": 137741087,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1292440985/image_1292440985.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Pfizer (PFE) is reiterated as a Buy, supported by the world's largest drug pipeline and trading below intrinsic value, despite near-term headwinds.",
      "url": "https://finnhub.io/api/news?id=50a8085ce11f95d1bb6dc7007d3590bbd4a61b3fe225d7f33fd4c0332781e962"
    }
  },
  {
    "ts": null,
    "headline": "Strategic Pharma Collaborations Propel RCC Market Growth",
    "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
    "url": "https://finnhub.io/api/news?id=6e04a3b15082455c2494b7f8a2365f33615f168f67ba566f3eeb4b7fad3c09db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765276020,
      "headline": "Strategic Pharma Collaborations Propel RCC Market Growth",
      "id": 137740191,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The global advanced renal cell carcinoma (RCC) market is experiencing rapid growth driven by innovative treatment approaches, rising disease awareness, and an expanding patient base. Key factors include the adoption of targeted therapies and immunotherapies, personalized medicine, and strategic collaborations among industry leaders such as Pfizer, Merck & Co., and AstraZeneca.Dublin, Dec. 09, 2025 (GLOBE NEWSWIRE) -- The \"Advanced Renal Cell Carcinoma (RCC) Market - A Global and Regional Analysi",
      "url": "https://finnhub.io/api/news?id=6e04a3b15082455c2494b7f8a2365f33615f168f67ba566f3eeb4b7fad3c09db"
    }
  },
  {
    "ts": null,
    "headline": "Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500",
    "summary": "Read the list of top S&P 500 high-yield dividend stocks with strong upside, safer payouts, and analyst forecasts for 21%+ gains by 2026.",
    "url": "https://finnhub.io/api/news?id=3e2eff974daf357a75332437eed5f5037273a550495eac4a88fd8f471f6a9d3f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765275333,
      "headline": "Here's 12 Ideal 'Safer' December Dividend Dogs Of The S&P500",
      "id": 137740872,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2173206826/image_2173206826.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Read the list of top S&P 500 high-yield dividend stocks with strong upside, safer payouts, and analyst forecasts for 21%+ gains by 2026.",
      "url": "https://finnhub.io/api/news?id=3e2eff974daf357a75332437eed5f5037273a550495eac4a88fd8f471f6a9d3f"
    }
  },
  {
    "ts": null,
    "headline": "CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response",
    "summary": "By John Vandermosten, CFA NASDAQ:CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful development and commercialization of onvansertib for first line treatment of patients with metastatic colorectal cancer (mCRC). Onvansertib is a Polo-Like kinase 1 (PLK1)",
    "url": "https://finnhub.io/api/news?id=1e9d0d92d24e4562766dc243593fcef442669b61f53068a1c9bd8fb36eb42f5c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1765272120,
      "headline": "CRDF: Initiating Coverage – Combination Therapy Elicits Superior Response",
      "id": 137740284,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "By John Vandermosten, CFA NASDAQ:CRDF READ THE FULL CRDF RESEARCH REPORT We are initiating coverage of Cardiff Oncology, Inc. (NASDAQ:CRDF) with a valuation of $8.50 per share. This value is based on our estimates for successful development and commercialization of onvansertib for first line treatment of patients with metastatic colorectal cancer (mCRC). Onvansertib is a Polo-Like kinase 1 (PLK1)",
      "url": "https://finnhub.io/api/news?id=1e9d0d92d24e4562766dc243593fcef442669b61f53068a1c9bd8fb36eb42f5c"
    }
  }
]